R
Richard H. Wheeler
Researcher at University of Utah
Publications - 66
Citations - 9167
Richard H. Wheeler is an academic researcher from University of Utah. The author has contributed to research in topics: Head and neck cancer & Chemotherapy. The author has an hindex of 27, co-authored 66 publications receiving 8348 citations. Previous affiliations of Richard H. Wheeler include State University of New York System & University of Alabama.
Papers
More filters
Journal ArticleDOI
Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer
K. Kian Ang,Jonathan Harris,Richard H. Wheeler,Randal S. Weber,David I. Rosenthal,Phuc Felix Nguyen-Tân,William H. Westra,Christine H. Chung,Richard C.K. Jordan,Charles Lu,Harold Kim,Rita Axelrod,C Craig Silverman,Kevin P. Redmond,Maura L. Gillison +14 more
TL;DR: Tumor HPV status is a strong and independent prognostic factor for survival among patients with oropharyngeal cancer and the risk of death significantly increased with each additional pack-year of tobacco smoking.
Journal ArticleDOI
Mouse/human chimeric monoclonal antibody in man: kinetics and immune response
Albert F. LoBuglio,Richard H. Wheeler,John M. Trang,Amy Haynes,Kim Rogers,Elizabeth B. Harvey,Lee Sun,John Ghrayeb,M. B. Khazaeli +8 more
TL;DR: This chimeric form of 17-1A mAb has an approximate 6-fold longer circulation time and appears to be substantially less immunogenic than its murine counterpart, which may provide an advantage in the clinical application of such chimeric molecules in therapeutic trials in humans.
Journal ArticleDOI
Phase I Study of Anti–Epidermal Growth Factor Receptor Antibody Cetuximab in Combination With Radiation Therapy in Patients With Advanced Head and Neck Cancer
Francisco Robert,Mark P. Ezekiel,Sharon A. Spencer,Ruby F. Meredith,James A. Bonner,M. B. Khazaeli,Mansoor N. Saleh,Delicia Carey,Albert F. LoBuglio,Richard H. Wheeler,Michael R. Cooper,Harlan W. Waksal +11 more
TL;DR: The most commonly reported adverse events were fever, asthenia, transaminase elevation, nausea, and skin toxicities (grade 1 to 2 in most patients).
Journal ArticleDOI
Final report of rtog 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck
Sharon A. Spencer,Jonathan Harris,Richard H. Wheeler,Mitchell Machtay,Christopher J. Schultz,William Spanos,Marvin Rotman,Ruby F. Meredith,K. Kian Ang +8 more
TL;DR: The objectives were to determine the incidence of acute and late toxicities and to estimate the 2‐year overall survival for patients treated with reirradiation and chemotherapy for unresectable squamous cell carcinoma of the head and neck (SCCHN).
Journal ArticleDOI
Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation.
Mansoor N. Saleh,Kevin P. Raisch,Murray A. Stackhouse,William E. Grizzle,James A. Bonner,Matthew S. Mayo,Hyung-Gyoon Kim,Ruby F. Meredith,Richard H. Wheeler,Donald J. Buchsbaum +9 more
TL;DR: C225-mediated apoptosis and inhibition of EGFr phosphorylation may be critical in the interaction and studies to define the precise influence of combined modality treatment on the EGFr signal transduction cascade need to be pursued.